Novel fluorinated pyrrolomycins as potent anti-staphylococcal biofilm agents

Design, synthesis, pharmacokinetics and antibacterial activities

Zunhua Yang, Yan Liu, Jongsam Ahn, Zhen Qiao, Jennifer L. Endres, Nagsen Gautam, Yunlong Huang, Jerry Li, Jialin C Zheng, Yazen Alnouti, Kenneth W Bayles, Rongshi Li

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Staphylococcus aureus (SA) is a major cause of hospital- and community-associated bacterial infections in the U.S. and around the world. These infections have become increasingly difficult to treat due to the propensity to develop antibiotic resistance and form biofilm. To date, no antibiofilm agents are available for clinical use. To add to the repertoire of antibiotics for clinical use and to provide novel agents for combating both SA and biofilm infections, we previously reported marinopyrroles as potent anti-SA agents. In this study, we used fragment-based and bioisostere approaches to design and synthesize a series of novel fluorinated pyrrolomycins for the first time, performed analyses of their physicochemical and drug-like properties, and investigated structure activity relationships and pharmacokinetics. These promising fluorinated pyrrolomycins demonstrate potent antibacterial activity against SA with favorable drug-like properties and pharmacokinetic profiles. Importantly, these compounds kill staphylococcal biofilm-associated cells with a lack of mammalian cell cytotoxicity and no occurrence of bacterial resistance. Our novel fluorinated pyrrolomycin 4 has a clogP value of 4.1, an MIC of 73 ng/mL, MBC of 4 μg/mL, kill staphylococcal-associated biofilm at 8 μg/mL, bioavailability of 35%, and the elimination half-life of 6.04 h and 6.75 h by intravenous and oral administration, respectively. This is the first report of comprehensive drug discovery studies on pyrrolomycin-based antibiotics.

Original languageEnglish (US)
Pages (from-to)129-137
Number of pages9
JournalEuropean Journal of Medicinal Chemistry
Volume124
DOIs
StatePublished - Jan 1 2016

Fingerprint

Pharmacokinetics
Biofilms
Staphylococcus aureus
Anti-Bacterial Agents
Drug Discovery
Structure-Activity Relationship
Cytotoxicity
Microbial Drug Resistance
Infection
Bacterial Infections
Pharmaceutical Preparations
Intravenous Administration
Biological Availability
Oral Administration
Half-Life
Cells

Keywords

  • Antibiofilm
  • Antibiotic drug discovery
  • Pyrrolomycin
  • SAR optimization
  • Staphylococcus aureus

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

Novel fluorinated pyrrolomycins as potent anti-staphylococcal biofilm agents : Design, synthesis, pharmacokinetics and antibacterial activities. / Yang, Zunhua; Liu, Yan; Ahn, Jongsam; Qiao, Zhen; Endres, Jennifer L.; Gautam, Nagsen; Huang, Yunlong; Li, Jerry; Zheng, Jialin C; Alnouti, Yazen; Bayles, Kenneth W; Li, Rongshi.

In: European Journal of Medicinal Chemistry, Vol. 124, 01.01.2016, p. 129-137.

Research output: Contribution to journalArticle

@article{4a3987d0d04a471a8677642aa22a2970,
title = "Novel fluorinated pyrrolomycins as potent anti-staphylococcal biofilm agents: Design, synthesis, pharmacokinetics and antibacterial activities",
abstract = "Staphylococcus aureus (SA) is a major cause of hospital- and community-associated bacterial infections in the U.S. and around the world. These infections have become increasingly difficult to treat due to the propensity to develop antibiotic resistance and form biofilm. To date, no antibiofilm agents are available for clinical use. To add to the repertoire of antibiotics for clinical use and to provide novel agents for combating both SA and biofilm infections, we previously reported marinopyrroles as potent anti-SA agents. In this study, we used fragment-based and bioisostere approaches to design and synthesize a series of novel fluorinated pyrrolomycins for the first time, performed analyses of their physicochemical and drug-like properties, and investigated structure activity relationships and pharmacokinetics. These promising fluorinated pyrrolomycins demonstrate potent antibacterial activity against SA with favorable drug-like properties and pharmacokinetic profiles. Importantly, these compounds kill staphylococcal biofilm-associated cells with a lack of mammalian cell cytotoxicity and no occurrence of bacterial resistance. Our novel fluorinated pyrrolomycin 4 has a clogP value of 4.1, an MIC of 73 ng/mL, MBC of 4 μg/mL, kill staphylococcal-associated biofilm at 8 μg/mL, bioavailability of 35{\%}, and the elimination half-life of 6.04 h and 6.75 h by intravenous and oral administration, respectively. This is the first report of comprehensive drug discovery studies on pyrrolomycin-based antibiotics.",
keywords = "Antibiofilm, Antibiotic drug discovery, Pyrrolomycin, SAR optimization, Staphylococcus aureus",
author = "Zunhua Yang and Yan Liu and Jongsam Ahn and Zhen Qiao and Endres, {Jennifer L.} and Nagsen Gautam and Yunlong Huang and Jerry Li and Zheng, {Jialin C} and Yazen Alnouti and Bayles, {Kenneth W} and Rongshi Li",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.ejmech.2016.08.017",
language = "English (US)",
volume = "124",
pages = "129--137",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Novel fluorinated pyrrolomycins as potent anti-staphylococcal biofilm agents

T2 - Design, synthesis, pharmacokinetics and antibacterial activities

AU - Yang, Zunhua

AU - Liu, Yan

AU - Ahn, Jongsam

AU - Qiao, Zhen

AU - Endres, Jennifer L.

AU - Gautam, Nagsen

AU - Huang, Yunlong

AU - Li, Jerry

AU - Zheng, Jialin C

AU - Alnouti, Yazen

AU - Bayles, Kenneth W

AU - Li, Rongshi

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Staphylococcus aureus (SA) is a major cause of hospital- and community-associated bacterial infections in the U.S. and around the world. These infections have become increasingly difficult to treat due to the propensity to develop antibiotic resistance and form biofilm. To date, no antibiofilm agents are available for clinical use. To add to the repertoire of antibiotics for clinical use and to provide novel agents for combating both SA and biofilm infections, we previously reported marinopyrroles as potent anti-SA agents. In this study, we used fragment-based and bioisostere approaches to design and synthesize a series of novel fluorinated pyrrolomycins for the first time, performed analyses of their physicochemical and drug-like properties, and investigated structure activity relationships and pharmacokinetics. These promising fluorinated pyrrolomycins demonstrate potent antibacterial activity against SA with favorable drug-like properties and pharmacokinetic profiles. Importantly, these compounds kill staphylococcal biofilm-associated cells with a lack of mammalian cell cytotoxicity and no occurrence of bacterial resistance. Our novel fluorinated pyrrolomycin 4 has a clogP value of 4.1, an MIC of 73 ng/mL, MBC of 4 μg/mL, kill staphylococcal-associated biofilm at 8 μg/mL, bioavailability of 35%, and the elimination half-life of 6.04 h and 6.75 h by intravenous and oral administration, respectively. This is the first report of comprehensive drug discovery studies on pyrrolomycin-based antibiotics.

AB - Staphylococcus aureus (SA) is a major cause of hospital- and community-associated bacterial infections in the U.S. and around the world. These infections have become increasingly difficult to treat due to the propensity to develop antibiotic resistance and form biofilm. To date, no antibiofilm agents are available for clinical use. To add to the repertoire of antibiotics for clinical use and to provide novel agents for combating both SA and biofilm infections, we previously reported marinopyrroles as potent anti-SA agents. In this study, we used fragment-based and bioisostere approaches to design and synthesize a series of novel fluorinated pyrrolomycins for the first time, performed analyses of their physicochemical and drug-like properties, and investigated structure activity relationships and pharmacokinetics. These promising fluorinated pyrrolomycins demonstrate potent antibacterial activity against SA with favorable drug-like properties and pharmacokinetic profiles. Importantly, these compounds kill staphylococcal biofilm-associated cells with a lack of mammalian cell cytotoxicity and no occurrence of bacterial resistance. Our novel fluorinated pyrrolomycin 4 has a clogP value of 4.1, an MIC of 73 ng/mL, MBC of 4 μg/mL, kill staphylococcal-associated biofilm at 8 μg/mL, bioavailability of 35%, and the elimination half-life of 6.04 h and 6.75 h by intravenous and oral administration, respectively. This is the first report of comprehensive drug discovery studies on pyrrolomycin-based antibiotics.

KW - Antibiofilm

KW - Antibiotic drug discovery

KW - Pyrrolomycin

KW - SAR optimization

KW - Staphylococcus aureus

UR - http://www.scopus.com/inward/record.url?scp=84994361423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994361423&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2016.08.017

DO - 10.1016/j.ejmech.2016.08.017

M3 - Article

VL - 124

SP - 129

EP - 137

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -